The approval of targeted therapies for esophageal, gastroesophageal junction, and gastric cancers has upended the treatment landscape, making timely access to, and accurate interpretation of, molecular testing critical for individualized treatment plans. Tune in to this webcast to hear experts discuss optimizing treatment selection with biomarker testing and other patient- and disease-specific factors, as well as share best practices on advancing gastric/esophagogastric cancer care in federal, public, and government health care settings.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/enhancing-timely-access-care-patients-solid-tumor-malignancies-federal-public
- Start Date: 2024-03-19 05:00:00
- End Date: 2024-03-19 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 10714.29 - Is Kind Support: False Source: Aveo Pharmaceuticals - Amount: 3214.29 - Is Kind Support: False Source: Bayer (Any division) - Amount: 1428.57 - Is Kind Support: False Source: Merck (Any division) - Amount: 10714.29 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 7142.86 - Is Kind Support: False Source: Seagen Inc. - Amount: 5357.14 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest